Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:04:49.632Z.
Consensus retrieved: 2026-10-06T15:14:17.457Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:04:49.632Z.
Quote observation: 2026-10-06T17:59:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ca628ff6f55b6345e2cefca22780bd34dfabddebf8a5c62bf0c86d2d29f40561
Forward PE Ratio (N/A) = Dated Quote Price ($1.00) / Consensus Forward EPS ($-1.44)
FORWARD PE RATIO
N/A
Phio Pharmaceuticals Corp.
Market Cap
$11.62M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | $11.62M | N/A |
| Biofrontera Inc. (BFRI)vs › | $11.47M | N/A |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.36M | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.12M | N/A |
| Caring Brands, Inc. (CABR)vs › | $11.09M | N/A |
| BioVie Inc. (BIVI)vs › | $11.05M | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.19M | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.90M | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.89M | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.83M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.00, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.45 | $-1.46 – $-1.42 | 2 | n/m |
| 2027-12-31 | $-0.61 | $-0.77 – $-0.45 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
